Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Non–Small Cell Lung Cancer

This study explores whether blood tumor mutational burden estimated by a next-generation sequencing gene panel is associated with clinical outcomes of patients with non–small cell lung cancer treated with anti–programmed cell death 1 and anti–programmed cell death ligand 1 agents.

https://ift.tt/2IId3G2